Pharmaron Beijing Co., Ltd.
Pharmaron Beijing Co., Ltd.
Share · CNE100003JW4 (XSHE)
Overview
No Price
Closing Price XSHE 30.10.2025: 33,14 CNY
30.10.2025 07:04
Current Prices from Pharmaron Beijing Co., Ltd.
ExchangeTickerCurrencyLast TradePriceDaily Change
XSHE: SHENZHEN STOCK EXCHANGE
SHENZHEN STOCK EXCHANGE
300759.SZ
CNY
30.10.2025 07:04
33,14 CNY
-0,91 CNY
-2,67 %
Share Float & Liquidity
Free Float 53,13 %
Shares Float 784,48 M
Shares Outstanding 1,48 B
Invested Funds

The following funds have invested in Pharmaron Beijing Co., Ltd.:

Fund
iShares MSCI EM ESG Enhanced UCITS ETF USD (Acc)
Vol. in million
468,39
Percentage (%)
0,04 %
Fund
iShares MSCI EM ESG Enhanced UCITS ETF USD (Dist)
Vol. in million
111,23
Percentage (%)
0,04 %
Fund
iShares MSCI China UCITS ETF USD (Dist)
Vol. in million
1,27
Percentage (%)
0,04 %
Fund
iShares MSCI EM IMI ESG Screened UCITS ETF USD (Acc)
Vol. in million
128,52
Percentage (%)
0,0081 %
Fund
iShares MSCI EM IMI ESG Screened UCITS ETF USD (Dist)
Vol. in million
25,39
Percentage (%)
0,0081 %
Company Profile for Pharmaron Beijing Co., Ltd. Share
Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides pharmaceutical research and development services to the life sciences industry in North America, Europe, Mainland China, rest of Asia, and internationally. The company operates through five segments: Laboratory Services; Chemistry, Manufacturing and Controls (CMC) Services; Clinical Development Services; Biologics and Cell and Gene Therapy Services; and Others. It offers laboratory chemistry solutions, including medicinal, synthetic, and analytical and purification chemistry, as well as computer-aided drug design services; bioscience services comprising in vitro and in vivo drug metabolism and pharmacokinetics/absorption, distribution, metabolism, and excretion solutions; and in vitro biology and in vivo pharmacology, safety assessment, and the U.S. laboratory services. The company also provides process development and manufacturing, material science/pre-formulation, formulation development and manufacturing, and analytical development services; and radiolabelled science services and early stage clinical trial services, as well as clinical research and site management services. It also provides business development; and contract research, development, and manufacturing services for pharmaceutical products. The company was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Get up to date insights from finAgent about Pharmaron Beijing Co., Ltd.

Company Data

Name Pharmaron Beijing Co., Ltd.
Company Pharmaron Beijing Co., Ltd.
Website https://www.pharmaron.com
Primary Exchange XSHE SHENZHEN STOCK EXCHANGE
ISIN CNE100003JW4
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Boliang Lou
Market Capitalization 47 Mrd.
Country China
Currency CNY
Employees 21,4 T
Address 6 Taihe Road, 100176 Beijing
IPO Date 2019-01-28

Ticker Symbols

Name Symbol
SHENZHEN STOCK EXCHANGE 300759.SZ
More Shares
Investors who hold Pharmaron Beijing Co., Ltd. also have the following shares in their portfolio:
IMMOFINANZ 19/23
IMMOFINANZ 19/23 Bond
OEKB 23/26 MTN
OEKB 23/26 MTN Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025